STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled the release of its full year 2024 financial results for March 19, 2025. The company will conduct a live webcast at 8:30 a.m. Eastern Time to present the financial results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com


FAQ

When will Liquidia (LQDA) release its full year 2024 financial results?

Liquidia will release its full year 2024 financial results on Wednesday, March 19, 2025.

What time is Liquidia's (LQDA) earnings webcast scheduled for March 19, 2025?

The earnings webcast is scheduled for 8:30 a.m. Eastern Time on March 19, 2025.

Where can investors access Liquidia's (LQDA) March 2025 earnings webcast?

Investors can access the webcast on Liquidia's website at liquidia.com/investors/events-and-presentations.

How long will Liquidia's (LQDA) March 2025 earnings webcast be available for replay?

The webcast will be archived and available for replay for one year on Liquidia's website.
Liquidia Corporation

NASDAQ:LQDA

LQDA Rankings

LQDA Latest News

LQDA Latest SEC Filings

LQDA Stock Data

2.76B
74.36M
13.61%
70.58%
19.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
MORRISVILLE